Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer

NCT02842294 · clinicaltrials.gov ↗

UNKNOWN

Status

320

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer
Quality of Life

Interventions

DRUG: Bevacizumab

Sponsor

Centre Hospitalier Universitaire de Besancon